SGO 2022 Annual Meeting Cervical Cancer Studies

As an ovarian cancer survivor, I normally concentrate my posts on ovarian cancer but there were a number of very interesting  cervical cancer and endometrial cancer studies/results presented at the SGO annual meeting. 

This post will focus on the cervical cancer sessions.

Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress

Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer -  Monk

 

Pembro is not statistically better, but numerically better on PROs for metastatic/recurrent cervical cancer. #keynote826 #SGOMtg #cervixcancer pic.twitter.com/Bhs5rqA84r

— Erin Stevens (@erinstevensmd) March 18, 2022

 

Safety and Immunogenicity of Anti PD-L1 (Atezolizumab) Given as an Immune Primer or Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer: an NRG Oncology Trial –  J. Mayadev 

 

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: a Cost-Effectiveness Analysis –  D. Barrington  

 

 

 

 

Scientific Plenary III: Novel Therapeutics: The Expanding Toolbox

 

Efficacy and Safety of Serplulimab (an anti-PD-1 antibody) Combined with Albumin-Bound Paclitaxel in Patients with Advanced Cervical Cancer who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy – J. An

 

 

 

 

#SGOmtg Serplulimab (an anti-PD-1 antibody) Combined with Albumin-Bound Paclitaxel in Patients w/ Advanced Cervical Cancer who Have progressive disease Dr An
57% had ORR , mPFS was 5.7 mo , mOS 15.5 mo
Manageable toxicity #gyncsm

— Dee Sparacio (@womenofteal) March 19, 2022

 

 

Efficacy and Safety of Cadonilimab, an Anti-PD-1/CTLA4 Bi-Specific Antibody, in Previously Treated Recurrent or Metastatic (R/M) Cervical Cancer: A Multicenter, Open-Label, Single-Arm, Phase II Trial – Speaker: X. Wu

 

#SGOmtg Efficacy and Safety of Cadonilimab, an Anti-PD-1/CTLA4 Bi-Specific Antibody, in
Previously Treated R/M Cervical Cancer: X. Wu
ORR 33% - 12 patients had a CR and 21 PR
Responded regardless of PDL1 status #gyncsm

— Dee Sparacio (@womenofteal) March 19, 2022

Open vs. Minimally Invasive Radical Hysterectomy in Early Cervical Cancer: LACC Trial Final Analysis – R. Ramirez I recalled the initial discussion/ debate on minimally invasive hysterectomy vs open surgery at an ASCO meeting a few years ago. Minimal invasive hysterectomy surgery should not be used.

 

 

 

 

The next post will report on some endometrial cancer  studies

Dee 

Every Day is a Blessing!

2021 SGO Virtual Meeting Sunday March 21, 2021

I am happy to share with you Tweets that cover the work presented during the last full day session of SGO was on Sunday, March 21, 2021.

One session, Time to Return to the Drawing Board, reported clinical trial results that did not meet their aims. Understanding where a drug or treatment may have failed to provide the results expected is as important as those trials that meet aims.

 Atezolizumab

#SGOMtg Association of BRCA1/2, HRD, and PD-L1 with clinical outcomes in patients receiving atezolizumab vs placebo combined with carbo, paclitaxel, and bev for newly dx
#gyncsm
Landen pic.twitter.com/qIc5j31bHD

— Dee Sparacio (@womenofteal) March 21, 2021

Falretuzumab

#SGOMtg
Phase 2 study to assess the efficacy/safety of farletuzumab in combo with carboplatin plus paclitaxel or carbo plus pegylated liposomal doxorubicin in women w/ low CA125 ( less than 3xs upper level
T. Herzog
Efficacy - no difference
PFS no difference #gyncsm pic.twitter.com/Xq98SqtXS4

— Dee Sparacio (@womenofteal) March 21, 2021

Dr. Herzog presents negative study of addition of farletuzumab (folate receptor alpha mAB) to chemo in pts with platinum sensitive #ovariancancer with CA-125 less than 3x ULN. No improvement in PFS or OS with the addition of the novel agent. #SGOMtg #gyncsm pic.twitter.com/dJq7g8fqSy

— Shannon Westin (@ShannonWestin) March 21, 2021

 

Durvalumab and Trememlimumab

#SGOMtg
Phase II Durvalumab (anti-PDL1)& Tremelimumab (anti-CTLA4) Administered in Combo versus Sequentially for the Treatment of Recurrent PR HGSOC
No diff between arms in PFS
Clear cell histology should be examined
E. Hinchcliff #gyncsm pic.twitter.com/ky6BBP72ZG

— Dee Sparacio (@womenofteal) March 21, 2021

phase II durvalumab and tremelimumab with front-line neoadjuvant chemo in patients with advanced-stage epithelial ovarian cancer
J. Lee
Manageable AEs
NACT increase in CD8T, PDL1 expression#gyncsm pic.twitter.com/iOhbYrcnys

— Dee Sparacio (@womenofteal) March 21, 2021

Additional sessions of interest.

Barriers to Quality of Care - Poster 

Significant barriers and challenges to receipt of quality care in #ovariancancer were identified. How do we raise the bar in access and treatment in this disease? #gyncsm #SGOMtg #sgo2021 pic.twitter.com/t2FJ3PW5Ew

— Sarah Temkin (@temkins) March 22, 2021

Uterine lavage and early detection

GynOnc Fellow Talayeh Ghezelayagh wowed the audience with her featured poster on uterine lavage, a novel early detection method for ovarian cancer. Great Q&A demonstrated her comfort with this high tech genomic study- great mentorship Dr. Rosana Risques.@UWMedicine @UWashOBGYN pic.twitter.com/SR23kC8f0H

— liz swisher (@SwisherLiz) March 21, 2021

Post operative opiods use model 

@BrittDavidsonmd: Development and validation of the Gynecologic Oncology Predictor of Postoperative opioid use (go-pop) model at #SGOMtg I love GO-POP's potential to provide ALL patients with the amount of pain control that they need #SGOPatAdv pic.twitter.com/SpYhoRxIEU

— Annie Ellis (@Stigetta) March 21, 2021

Neuropathy and genetic variants 

Lauren Thomaier presents Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors at #SGOMtg Fantastic work to identify patients most at risk of CIPN! Very important! #SGOPatAdv #GYNcsm pic.twitter.com/GCeSoRXWn3

— Annie Ellis (@Stigetta) March 21, 2021

Gross resection and OS / NACT

Great study by @NiteckiRoni showing complete gross resection still remains integral to improving OS and ability to get R0 should inform surgical timing, not number of NACT cycles. @MDAndersonNews @SGO_org #SGO2021 #SGOMtg @RauhHainMD pic.twitter.com/uQAIl0KygU

— Jeffrey How (@jahow514) March 21, 2021

#SGOmtg Surgical Debulking improves survival in high-grade serous carcinoma regardless of platinum sensitivity
N. Cardillo #gyncsm
Retrospective
Optimal surgery is an independent predictor of survival. pic.twitter.com/BpYuZGX4bK

— Dee Sparacio (@womenofteal) March 21, 2021

Partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer-time for surgery or more chemotherapy?
R. Nitecki
Retrospective study , Phys choice more chemo or surgery 2013-2019
residual disease drives survival#SGOMtg #gyncsm pic.twitter.com/VRh51mdXGm

— Dee Sparacio (@womenofteal) March 21, 2021

Vulvar Cancer Studies 

The accuracy of intraoperative frozen section examination of sentinel lymph nodes in squamous cell cancer of the vulva
B. Swift
snl = sentinel lymph nodes #SGOMtg #gyncsm pic.twitter.com/1ddaquo643

— Dee Sparacio (@womenofteal) March 21, 2021

Volume-outcome relationship in vulvar cancer treatment: A Japanese Gynecologic Oncology Group Study

S. Nishio#SGOMtg#gyncsm
>1000 women
no association of hospital volume relationship and PFS pic.twitter.com/0fsEp7Lfnk

— Dee Sparacio (@womenofteal) March 21, 2021

#SGOMtg Vulvar Cancer Research
Pembrolizumab for vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study
R. Shapira Frommer
Responses independent of PDL-1 status. #gyncsm pic.twitter.com/IJj1eLjdpg

— Dee Sparacio (@womenofteal) March 21, 2021

Endometrial cancer 

Cediranib and Olaparib NRG GY012

Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
BJ Rimel NRG GY012 study #SGOMtg
#gyncsm
Did not m pic.twitter.com/YxDK8S565f

— Dee Sparacio (@womenofteal) March 21, 2021

IUD

#SGOMtg
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: @AndreasObermair 165 patients
Weight loss may help response. #gyncsm pic.twitter.com/zfh3cc9WiN

— Dee Sparacio (@womenofteal) March 21, 2021

 Enzalutamide

#SGOMtg ENPAC: Phase II trial with safety lead of enzalutamide in combination with paclitaxel and carbofor adv or recurrent endometrioid endometrial adenocarcinoma
Westin #gyncsm health moderator
Andogen receptor expressed in endometroid OC , 35 patients
tolerable. pic.twitter.com/r8ZS9Nfijc

— Dee Sparacio (@womenofteal) March 21, 2021

Here are some articles from various sources that go more into depth about studies discussed at the meeting. 

Medscape article on hormone IUD and endometrial cancer https://www.medpagetoday.com/meetingcoverage/sgo/91740

Vulvar cancer patients with sentinel node micrometastases, radiation therapy (RT) to the groin after local excision led to extremely low rates of recurrence, a phase II trial suggested https://www.medpagetoday.com/meetingcoverage/sgo/86603 

ABV-500 small molecule in OC https://www.medpagetoday.com/meetingcoverage/sgo/91739

 

Thank you so Eisai for supporting patient advocates at the annual meeting . 

Thank you SGO leadership for making us feel welcome and for all the gyn oncs who answered our questions.  

Dee

Every Day is a Blessing!